Samsung Biologics

Samsung Biologics is a South Korean contract development and manufacturing organization headquartered in Songdo, Incheon. Established in 2011 as the biotechnology division of Samsung Group, it manufactures biologic drugs for pharmaceutical partners, from late stage drug development through large scale commercial production, with a focus on monoclonal antibodies, bispecific antibodies, antibody drug conjugates and mRNA vaccines. Its client roster includes major pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol Myers Squibb. As of 2025 the company employed about 5,300 people and reported 2024 revenue of 4.55 trillion South Korean won with operating income of 325.7 billion won. This description is adapted from Wikipedia contributors under CC BY-SA 4.0; changes were made. https://creativecommons.org/licenses/by-sa/4.0/